深度及超深度PSA反应作为转移性激素敏感性前列腺癌的预后生物标志物。一项系统综述及对治疗个体化的启示。
完整摘要 · 中文译文
背景:转移性激素敏感性前列腺癌(mHSPC)尽管接受标准雄激素剥夺治疗(ADT)以及广泛采用雄激素受体通路抑制剂(ARPIs)和/或多西他赛进行一线强化治疗,其结局仍呈现异质性。需要简单、广泛可及的生物标志物来实现个体化治疗(强化 vs 降阶梯)。我们系统综述了治疗后PSA动态变化——特别是深度(≤ 0.2 ng/mL)和超深度(≤ 0.02 ng/mL)PSA应答——的预后价值及其在指导未来预测策略中的潜在作用。 方法:我们检索了MEDLINE和EMBASE中关于mHSPC接受单纯ADT或联合化疗、ARPIs和/或原发灶放疗的随机试验和观察性研究。主要结局为总生存期(OS)、影像学无进展生存期(rPFS)/无进展生存期(PFS)以及至去势抵抗时间(TTCR)。各研究中治疗后PSA评估时间窗不一(通常为3-7个月),锚定时间点为ADT启动或随机化(既往ADT暴露时间不等)。此外,我们检索了clinicaltrials.gov中正在进行的PSA指导治疗适应性临床试验。 结果:共识别785条记录,其中65篇文献符合纳入标准,对应16项III期随机试验、1项荟萃分析和42项回顾性研究。III期试验评估了不同治疗策略,包括单纯ADT、ADT联合多西他赛、ADT联合雄激素受体通路抑制剂(ARPIs;阿帕他胺、阿比特龙、达罗他胺、恩扎卢 酰胺或瑞维鲁胺)以及三联疗法。在各项试验中,深度和超深度早期PSA缓解始终与更长的rPFS和OS相关。相反,较高的PSA最低值或不完全的早期PSA缓解预示更早进展和更短生存。观察性队列显示了一致的结果。此外,本文总结了八项具有里程碑意义的PSA引导适应性随机临床试验(七项正在进行或计划中,一项近期已报告),包括对PSA缓解最佳患者的治疗降阶梯策略和对PSA缓解欠佳患者的治疗强化策略。 结论:在开始全身治疗后实现深度或超深度PSA缓解是mHSPC中稳健且可负担的预后指标。PSA评估窗口和阈值的统一至关重要。正在进行的随机试验将有助于理解其用于治疗个体化的价值。
完整摘要 · 英文原文
BACKGROUND: Metastatic hormone-sensitive prostate cancer (mHSPC) exhibits heterogeneous outcomes despite standard androgen deprivation therapy (ADT) and widespread first-line intensification with androgen-receptor pathway inhibitors (ARPIs) and/or docetaxel. Simple, widely accessible biomarkers are needed to individualize care (intensification vs de-intensification). We systematically reviewed the prognostic value of post-therapy PSA dynamics-particularly deep (≤ 0.2 ng/mL) and ultra-deep (≤ 0.02 ng/mL) PSA responses-and their potential role to inform future predictive strategies. METHODS: We searched MEDLINE and EMBASE for randomized trials and observational studies in mHSPC treated with ADT alone or combined with chemotherapy, ARPIs and/or radiotherapy to the primary tumor. Primary outcomes were overall survival (OS), radiographic progression-free survival (rPFS)/PFS, and time to castration resistance (TTCR). Post-therapy PSA assessment windows varied across studies (typically 3-7 months), and the anchoring time point was either ADT initiation or randomization (with variable prior ADT exposure). In addition, we reviewed clinicaltrials.gov for PSA-guided treatment adaptative ongoing clinical trials. RESULTS: Of 785 records identified, 65 references met the eligibility criteria, corresponding to 16 phase III randomized trials, 1 meta-analysis and 42 retrospective studies. The phase III trials evaluated different treatment strategies, including ADT alone, ADT plus docetaxel, ADT plus androgen receptor pathway inhibitors (ARPIs; apalutamide, abiraterone, darolutamide, enzalutamide, or rezvilutamide), and triplet therapy. Across trials, deep and ultradeep early PSA responses were consistently associated with longer rPFS and OS. Conversely, higher PSA nadirs or incomplete early PSA responses predicted earlier progression and shorter survival. Observational cohorts showed concordant findings. In addition, eight landmark PSA-guided adaptive randomized clinical trials (seven ongoing or planned and one recently reported) were summarized, including treatment de-escalation strategies for patients with optimal PSA responses and treatment intensification strategies for those with suboptimal PSA responses. CONCLUSIONS: Achieving a deep or ultra-deep PSA response after starting systemic therapy is a robust and affordable prognostic indicator in mHSPC. Harmonization of PSA assessment windows and thresholds is crucial. Ongoing randomized trials will help to understand its utility for treatment personalization.